Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Paul D. Harker-Murray, Richard A. Drachtman, David C. Hodgson, Allen Russell Chauvenet, Kara M. Kelly, Peter David Cole

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579-586.

Original languageEnglish (US)
Pages (from-to)579-586
Number of pages8
JournalPediatric Blood and Cancer
Issue number4
StatePublished - Apr 2014


  • Chemotherapy
  • Hematopoietic cell transplant
  • Hodgkin lymphoma
  • Pediatric oncology
  • Relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this